Search

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Read more